Follow

• 

  Dietary supplement use among BRCA1/2 mutation carriers

  Ryan Rogers, Tara Ramgarajan, Virginia Uhley, Kristina Ivan, and Dana Zakalik

  Publication Date: 5-2-2022

  INTRODUCTION
  Women who carry BRCA1/2 mutations are at significantly increased risk of breast, ovarian, pancreatic and other cancer. Little is known regarding the use of dietary supplements among women harboring BRCA1/2 mutations. This study aims to characterize the utilization of and attitudes toward dietary supplement use in women who carry BRCA1/2 mutations.

• 

  A Rare Case of Subcutaneous Panniculitis-Like T-cell Lymphoma

  Blake Seelbinder, Angela Kim, Marcos Rosado, Mohamed Musheinesh, Amanda Cimino, John Pui, Armen Korkigian, and Craig Gordon

  Publication Date: 5-2022

  Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare and typically slow growing variant of T-cell lymphoma. The clinical course usually mimics infectious panniculitis. It characteristically affects the subcutaneous adipose tissue of the trunk or extremities without resultant lymph node involvement. It comprises

• 

  A Case of Pancreatic Squamous Cell Cancer

  Bijaya Thapa, Ujjwal Jung Karki, Bipin Ghimire, Ashbita Pokharel, Shailesh Niroula, and Mohammad Muhsin Chisti

  Publication Date: 10-2022

  Introduction

  Primary Squamous Cell Carcinoma of the pancreas is a rare entity that comprises 0.05% of all exocrine pancreatic carcinomas. The main differential diagnoses of primary SCC of the pancreas are adenosquamous carcinoma- another rare primary tumor of the pancreas and metastatic SCC from another primary site.

  Discussion

  Squamous cell carcinoma of the pancreas is a controversial entity of uncertain origin, as the pancreas is entirely devoid of squamous cells[1] • Adenosquamous carcinomas may be misdiagnosed in case of inadequate sampling of adenocarcinoma component. • Literature is limited to a few case reports, and has shown pancreatic SCC to be an aggressive cancer with a poor prognosis. • Isolated reports are available on the use of gemcitabine and newer taxane formulations, but the response to chemotherapy or radiotherapy is sub-optimal. • Similar to breast, ovarian, and endometrial cancers; pancreatic cancers can be genetically inherited. • As with all pancreatic cancers, surgical resection of the tumor has been the most effective modality, however treatment with targeted immunotherapy could be promising in unresectable tumors with targetable mutations.